Welcome to our dedicated page for Biomarin Pharmaceutical SEC filings (Ticker: BMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioMarin Pharmaceutical Inc. (BMRN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed rare disease biotechnology company, BioMarin files periodic and current reports that describe its financial condition, results of operations, governance changes and material corporate events.
Investors researching BMRN can review Forms 10-K and 10-Q for detailed discussions of BioMarin’s business, risk factors, rare disease portfolio and pipeline strategy. Current reports on Form 8-K, such as those announcing quarterly results, acquisitions, leadership changes or guidance updates, give insight into significant developments affecting the company’s Enzyme Therapies, Skeletal Conditions and gene therapy franchises.
Through this page, users can also track information that may appear in proxy materials and other filings, including board composition and committee appointments, executive roles and the company’s use of non-GAAP financial measures like Non-GAAP Operating Margin and Non-GAAP Diluted EPS, as described in its disclosures. For those monitoring corporate actions, merger agreements, or business development transactions, the related 8-K filings and exhibits are a primary source of official information.
Stock Titan enhances these filings with AI-powered summaries that explain key points in plain language, helping readers interpret long or technical documents. Real-time updates from EDGAR, combined with structured access to forms such as 10-K, 10-Q and 8-K, allow investors to follow BioMarin’s regulatory reporting history and understand how management communicates strategy, performance and risk to the market.
Q2 2025 highlights: BioMarin (BMRN) generated total revenue of $825.4 million, up 16% YoY, led by VOXZOGO (+20%) and VIMIZIM (+21%). Cost of sales grew in line with volume, while R&D (-12%) and SG&A (-12%) fell, expanding operating income to $276.9 million versus $120.5 million last year. Net income more than doubled to $240.5 million; diluted EPS rose to $1.23 from $0.55.
Margins & cash: Gross margin remained about 81.5%; operating margin widened to 33.5% (19.0% prior year). Operating cash flow climbed 117% to $359.7 million, lifting cash and equivalents to $1.21 billion. Convertible debt is unchanged at $600 million, leaving net leverage very low. Retained earnings swung to a $232 million surplus from a $(195) million deficit at year-end.
Product mix Q2 2025:
- VOXZOGO $221.4 m
- VIMIZIM $215.4 m
- NAGLAZYME $128.9 m
- PALYNZIQ $105.9 m
- ALDURAZYME $56.4 m
- BRINEURA $48.7 m
- KUVAN $27.0 m (generic erosion)
- ROCTAVIAN $9.2 m
Balance-sheet notes: Inventory increased 9% to $1.34 billion; AOCI turned to a $(44.6) million loss mainly from FX hedge marks. Three customers represent 38% of net product revenue.
Events after quarter-end: Closed $270 million all-cash acquisition of Inozyme Pharma, adding late-stage enzyme therapy BMN-401; assessing impact of newly enacted U.S. OBBB tax law.